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The telomerase enzyme is a potential therapeutic target in many
human cancers. A series of potent inhibitors has been designed by
computer modeling, which exploit the unique structural features of
quadruplex DNA. These 3,6,9-trisubstituted acridine inhibitors are
predicted to interact selectively with the human DNA quadruplex
structure, as a means of specifically inhibiting the action of human
telomerase in extending the length of single-stranded telomeric DNA.
The anilino substituent at the 9-position of the acridine chromophore
is predicted to lie in a third groove of the quadruplex. Calculated
relative binding energies predict enhanced selectivity compared with
earlier 3,6-disubstituted compounds, as a result of this substituent.
The ranking order of energies is in accord with equilibrium binding
constants for quadruplex measured by surface plasmon resonance
techniques, which also show reduced duplex binding compared with
the disubstituted compounds. The 3,6,9-trisubstututed acridines have
potent in vitro inhibitory activity against human telomerase, with
EC50 values of up to 60 nM.
The telomeric ends of chromosomes consist of tandem repeats ofsimple guanine-rich DNA protein-associated motifs whose
function is to protect the ends from unwanted DNA damage-repair,
recombination, and end-fusions. In eukaryotics the repeat is
TTAGGG, with telomere length varying between ca. 5 and 15 kb
(1, 2). Cancer cells typically have short telomeres, whereas stem cell
telomere length tends to be at the high end of this range. The
terminal 150–200 bases at the 39 end of human telomeres form a
single-stranded overhang, whose exact structure is not fully estab-
lished, although loop-type arrangements have been suggested from
electron microscope studies (3). Telomeres shorten in somatic cells
on each round of replication, by 50–200 bases, as a consequence of
the inability of DNA polymerase to fully replicate the ends (4).
Once telomeres reach a critically short length, cells enter a senes-
cent state and do not replicate further (5). By contrast, the short
telomeres in tumor cells are stable in length, maintained by the
action of a specialized DNA polymerase, the telomerase enzyme
complex, which catalyses the synthesis of further telomere repeats
(6). Telomerase is activated in 80–90% of human tumors and is
undetectable in most normal somatic cells (7). This activation has
been shown to be a key step in the immortalization process in
human cells, leading to tumorigenesis (8). A small proportion of
tumor cells have an alternative telomere maintenance pathway
(ALT) which appears to be independent of telomerase and involves
recombination events. Inhibition of telomerase by a dominant
negative mutant (9, 10), or by synthetic oligonucleotides targeted to
the RNA template (11), leads to telomere shortening, growth arrest
and apoptosis for tumor cells in culture. Telomerase is thus a highly
attractive target for selective anti-cancer therapy (12).
We have focused on the rational discovery of small-molecule
telomerase inhibitors with pharmacologically acceptable features,
and which are predicted to interact with the DNA telomere primer
strand rather than the enzyme itself. Telomerase requires the 39 end
of the primer to be single-stranded to effectively hybridize with the
enzyme’s endogenous RNA template, and possibly for effective
precession of the newly synthesized strand to occur. Folding of
telomeric DNA into four-stranded guanine-quadruplex (G4) struc-
tures (13) has been shown to inhibit the enzyme from catalyzing the
synthesis of further telomeric DNA repeats (14). Synthetic mole-
cules that stabilize such G4 structures may then be effective
telomerase inhibitors (15). A number of G4 inhibitors have been
identified, based on the tricyclic aromatic chromophores anthra-
quinones (16, 17), fluorenones (18), and acridines (19, 20), as well
as a perylenetetracarboxylic diimide derivative (21) and compounds
with a porphyrin skeleton (22). For the majority of these molecules
optimal activity has been achieved by substitution of side chains
possessing amidoalkylamino character. The best of these ligands
have telomerase activity of ca. 2–5 mM, expressed as the concen-
tration to inhibit 50% of enzymatic telomere-lengthening function;
acute cytotoxicities as measured by 96-h exposures in ovarian tumor
cell lines are also typically at this level (16–20).
The classic model for telomere maintenance by telomerase
suggests that inhibitors will require administration for a consid-
erable number of rounds of cell doubling for sufficient telomere
attrition to occur so that senescence is triggered. The requisite
concentration of inhibitor needs to be significantly below acute
toxicity levels, otherwise generalized cytotoxic cell kill will take
place instead. Conventional antitumor agents that bind to duplex
DNA typically produce their cytotoxic effect by interfering with
transcription or with the correct function of DNA topoisomer-
ases or other enzymes involved in DNA replication. The G4
inhibitors reported to date generally have affinity for duplex
DNA comparable to their quadruplex binding, and it is unsur-
prising that levels of cytotoxicity and telomerase inhibition also
have been found to be comparable (see above). Modest duplex
vs. quadruplex selectivity has been reported for some substituted
porphyrins (23). The hypothesis that telomerase inhibition oc-
curs via a quadruplex-mediated mechanism would be strongly
supported by a molecule that shows (i) G4 selectivity over duplex
DNA affinity, and (ii) increased potency for telomerase inhibi-
tion, together with a low level of acute cytotoxic activity.
G4 DNAs have several distinct structural features compared
with duplex DNA (13), notably the possession of four quasi-
equivalent grooves and a pronounced channel of negative elec-
trostatic potential running through the center of the planes of G
quartets, allowing metal ions to be coordinated between the
planes in a bipyramidal antiprismatic manner. We report here
the rational design and evaluation of a series of molecules that
take account of these features and that have enabled significant
G4 selectivity to be achieved. They are derived in part from our
earlier studies (16–20), which have resulted in compounds
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typified by the disubstituted acridine (1: Fig. 1). These showed
that simulating the energetics and geometry of ligand binding to
the structure of the human intramolecular G quadruplex formed
by the 22-mer d[AG3(TTAG3)3] provided good correlations with
their telomerase inhibition. This NMR-derived G4 structure (24)
has been used as a starting point for the present molecular design
studies, focusing on a single high-affinity binding site stacked on
one end of the plane of G quartets in the structure (25).
Materials and Methods
Molecular Modeling. The coordinates from one of the solution NMR
structures of the folded intramolecular G-quadruplex human telo-
meric repeat d[AG3(TTAG3)3] (Protein Data Bank entry 143D)
were taken as a starting model. It was initially subjected to
molecular mechanics energy minimization (1,000 steps steepest
descent and 3 3 1,000 steps Polak-Ribiere conjugate gradient),
followed by 140 ps of molecular dynamics simulation (1.5-fs time
step at 300 K). The subsequent time-averaged structure was further
minimized (1,000 steps steepest descent and 3 3 1,000 steps
Polak-Ribiere conjugate gradient) and used as the basis for all
further modeling studies. The AMBER 6.0 suite of molecular simu-
lation programs (26) and the Cornell et al. force field (27) were used
in these and subsequent computations.
A pseudointercalation ligand binding site was introduced be-
tween the diagonal T2A loop and the G-quartet segment of the
structure (at the 59 AG step) by breaking the two phosphate
backbones and separating the two halves of the structure so that the
separation of the A:A base pair and G quartet increased from 3.4
to 6.8 Å. The sugar-phosphate chains were reconnected, and
molecular mechanics energy minimization (1,000 steps steepest
descent followed by 1,000 steps conjugate gradient) was used to
relieve any resulting steric distortion while retaining the intercala-
tion geometry between G quartet and loop motifs by means of
appropriate positional restraints.
A molecular models of the acridine derivative 1 was built and
charges were allocated by using the AM1 semiempirical formalism
in the MOPAC package (28). The ligand then was minimized and
manually docked into the pseudointercalation site. Ligand positions
and orientations also were optimized with the AFFINITY docking
program, within the INSIGHT II suite (29). This program incorpo-
rates manual and automatic docking procedures and allows non-
bonded van der Waals and electrostatic interactions to be moni-
tored during the docking so that many possible conformations can
be interactively evaluated. A search also was made for other
high-affinity ligand binding sites on the quadruplex; none were
found of equivalent binding energy. Flexible ligand docking also
was used to define the lowest energy position for the ligand by using
a Monte Carlo automated docking protocol. The G quartets were
restrained to their original positions throughout the docking pro-
tocols. The final low energy conformation of the ligand then was
subjected to a further 500 steps of unrestrained molecular mechan-
ics minimization before it was transferred to the AMBER 6.0 suite.
The force-field parameters for the ligand were extrapolated from
existing values for analogous groups in the AMBER and CFF force
fields (29). Visual inspection together with chemical insight was
used to conceptualize derivatives of compound 1, which would
produce increased van der Waals contacts with the binding site.
Compounds 3 and 4 were designed in this way. Molecular dynamics
simulation computations on them and their complexes were per-
formed with protocols identical to those for compound 1.
DNA-ligand complexes were solvated in a periodic TIP3 water
box of dimensions ’60 3 60 3 60 Å, which extended at least 10 Å
from any solute atom. Two internal sodium ions were positioned in
the central channel between the three central G quartets by using
crystallographically determined distances from the d(TG4T) crystal
structure (13). The sodium ions were positioned to allow coordi-
nation with the four polarized carbonyl oxygens on the two adjacent
G quartets, completing the octahedral coordination sphere. Each
system then required an additional 18 sodium counter ions for
complete neutralization. These were positioned throughout the cell
at grid points of negative coulombic potential.
All calculations were carried out by using the Sander module of
AMBER 6.0 with the SHAKE algorithm enabled for the hydrogen
atoms and a 2-fs time step. The nonbonded pairs list was updated
every 20 steps. Each complex was subjected to 1,000 steps of
conjugate gradient minimization followed by 10 ps of equilibration
dynamics at 300 K with full constraints on the DNA complex and
a 12-Å nonbonded Lennard-Jones cutoff. The particle mesh Ewald
summation term was activated for all simulations to include long-
range electrostatic interactions in the calculations. The particle
mesh Ewald charge grid spacing was ’1.0 Å, and the charge grid
was chosen to be products of the powers of two, three, and five to
ensure efficiency of the fast Fourier transform calculation. Each
complex then was gradually allowed to relax as restraints were
sequentially lowered over seven successive rounds of conjugate
gradient minimizations. For dynamics runs after minimizations, the
initial velocities were assigned by using the standard Maxwellian
distributions. The final production run of 1,000 ps was then carried
out on a multiple-processor SGI Origin 200 computer. Coordinates
were written to the output files every 5 ps for the analysis of the
trajectory. Relative binding energies for all three compounds were
calculated by subtracting the total interaction energy of the explic-
itly solvated ligand and its surroundings in a neutral periodic box
from the identical system, when the ligand was bound to the folded
human G4 DNA structure. The resulting differences in interaction
energy correspond to relative binding energies. These procedures
did not produce meaningful binding energies for compound 2.
Attempts at simulating its binding resulted in distortions to the
quadruplex structure such that the ligand was shifted by 2.5–4 Å
from the bound positions of the other compounds, as a result of the
bulky side chains.
Preparation of 3,6,9-Trisubstituted Acridine Derivatives. Compounds
3 and 4 were synthesized by the routes shown in Fig. 2, via
acridone intermediates. Full details will be given elsewhere. In
both cases the final substitution step gave product in 88% yield.
Both compounds were analytically pure. Compounds 1 and 2
were synthesized as described (19).
Binding and Kinetic Studies. Surface plasmon resonance (SPR)mea-
surements were performed by using a BIACore 2000 system with
streptavidin-coated sensor chips (SA) for all experiments. This chip
consists of a gold surface and streptavidin covalently immobilized
on a carboxymethylated dextran layer at the surface. To prepare
sensor chips for use, they were conditioned with three consecutive
1-min injections of 1 M NaCl in 50 mM NaOH followed by extensive
washing with buffer. Biotinylated DNA (59-Biot-d[AG3(TTAG3)3])
in Hepes buffer, pH 7.4 [0.01 M Hepes, 0.15 M NaCl, 3 mM EDTA,
Fig. 1. Structures of compounds 1–4.
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and 0.005% (volyvol) Surfactant P20] was immobilized on the
surface by noncovalent capture to streptavidin. One of the flow
cells was used to immobilize the DNA and another served as a
control. Manual injection was used with 25 nM DNA and a flow
rate of 2 mlymin to achieve long contact times with the surface and
to control the amount of the DNA bound to the surface. This DNA
folded in the presence of K1 and formed a quadruplex during
extended flow in the SPR experiments. (Folding with respect to
time was checked by a series of meltingycooling experiments
assessed by both CD and UV methods; after several minutes of
cooling to 25°C, no further change in signals with respect to time
was observed.) A second channel of the sensor chip was left as a
blank reference. All procedures for binding studies were automated
by using repetitive cycles of sample injection and regeneration.
All ligand samples were dissolved in H2O (1 mM) and then
diluted as stock solution to 1E-4M in the running buffer, pH 7.4
(0.01 M Hepesy0.2 M KCly3 mM EDTAy50 mlyliter Surfactant
P20). Samples of each were prepared in filtered and degassed
buffer by serial dilutions from the stock solutions. The same
running buffer was used for regeneration of the surface.
Samples were injected at flow rates of 10–20 mlymin by using
the KINJECT command for steady-state experiments. A higher
flow rate of 100 mlymin was used for the kinetic experiments to
minimize mass transport effects and deliver a consistent sample
plug. Double referencing subtractions were used for data anal-
ysis. The first reference subtraction eliminates the bulk refractive
index change and injection noise whereas the second subtraction
of a blank buffer injection eliminates any systematic changes that
are characteristic of a particular cell. Details of the data analysis
will be given elsewhere.
Taq Polymerase Assay. Ligands were evaluated as their acid addition
hydrochloride salts at 10, 20, and 50 mM final concentrations in a
PCR 50 ml master mix containing 10 ng pCI-neo mammalian
expression vector (Promega) and forward d(GGAGTTCCGCGT-
TACATAAC) and reverse d(GTCTGCTCGAAGCATTAACC)
primers (200 nmol) as described (17). The product of ’1 kb was
visualized on a 2% (wtywt) agarose gel after amplification (30 cycles
of 94°C for 1 min, 55°C for 1 min, and 72°C for 2.5 min).
Modified Telomeric Repeat Amplification Protocol (TRAP) Assay. The
ability of compounds 1–4 to inhibit telomerase in a cell-free assay
was assessed with a modified TRAP assay using extracts from
exponentially growing A2780 human ovarian carcinoma cells as
described (17–19). The TRAP assay was performed in two steps: (i)
telomerase-mediated extension of the forward primer (TS: 59-
d(AATCCGTCGAGCAGAGTT), Oswel, Southampton, U.K.)
contained in a 40 ml reaction mix comprising TRAP buffer [20 mM
TriszHCl (pH 8.3)y68 mM KCly1.5 mM MgCl2y1 mM EGTAy
0.05% (vol/vol) Tween 20y0.05 mg BSAy50 mM of each deoxynucle-
otide triphosphatey0.1 mg TS primery3 mCi of [a-32P]dCTP (Am-
ersham Pharmacia)]. Protein (0.04 mg) then was incubated with the
reaction mix 6 agent (as acid addition salts) at final concentrations
of up to 50 mM for 20 min at 25°C. A lysis buffer (no protein)
control, heat-inactivated protein control, and 50% protein (0.02 mg)
control were included in each assay. (ii) While heating at 80°C in a
PCR block of a thermal cycler (Hybaid, Middlesex, U.K.) for 5 min
to inactivate telomerase activity, 0.1 mg of reverse CX primer
[39-d(AATCCCATTCCCATTCCCATTCCC-59)] and 2 units of
Taq DNA polymerase (‘‘red hot’’, Advanced Biotechnologies,
Columbia, MD) were added. A three-step PCR was then per-
formed: 94°C for 30 s, 50°C for 30 s, and 72°C for 1 min for 31 cycles.
Telomerase-extended PCR products in the presence or absence of
the ligands then were determined either by electrophoretic sepa-
ration using 8% (wtywt) acrylamide denaturing gels and analysis by
phosphorimaging or autoradiography, or by harvesting on What-
man filters (25-mm glass microfiber) and analysis by liquid scintil-
lation counting.
Growth Inhibition Assay. Growth inhibition was measured in three
telomerase-positive human ovarian carcinoma cell lines (A2780,
CH1, and SKOV-3) using the sulforhodamine B assay as described
(17–19). Briefly, between 3,000 and 6,000 cells were seeded into the
wells of 96-well microtiter plates and allowed to attach overnight.
Agents (acid addition and quaternary dimethiodide salts) were
dissolved at 500 mM in water and immediately added to wells in
quadruplicate at final concentrations of 0.05, 0.25, 1, 5, and 25 mM.
After an incubation period of 96 h, remaining cells were fixed with
ice-cold 10% (wtyvol) trichloroacetic acid (30 min) and stained with
0.4% sulforhodamine B in 1% (volyvol) acetic acid (15 min). Mean
absorbance at 540 nm for each drug concentration was expressed as
a percentage of the control untreated well absorbance, and IC50
values (concentration required to inhibit cell growth by 50%) were
determined for each agent.
Results
Molecular Modeling and Synthesis of Quadruplex-Selective Inhibitors.
The initial docking and subsequent dynamics simulations modeling
studies show that the planar chromophore of the di-substituted
acridine derivative 1 is stacked on the terminal G quartet in the 59
AG step site, between the 59 T2A loop and a terminal G-quartet
such that the cationic acridine ring nitrogen atom is overlapping the
central polarized carbonyl channel of negative electrostatic poten-
tial that runs through the stack of G quartets (Fig. 3a). The
chromophore is stabilised by p-p stacking interactions with the
terminal G quartet and the A:A base pair. The binding site itself is
highly asymmetric, and because it is external to the stack of three
G quartets, it is bounded by the grooves formed by the phosphodi-
ester backbones. The two substituent amidoalkylamino chains lie in
the two widest grooves, with the terminal pyrrolidine rings forming
favorable hydrophobic interactions with the sides of the grooves. A
Fig. 2. Synthetic schemes for the 3,6,9-trisubstituted acridine derivatives 3
and 4. The individual steps involved (i) KNO3yH2SO4, (ii) CrO3, AcOH, reflux, (iii)
ZnyHCl, 90–100°C, (iv) 3-CPC, reflux, (v) NHR2, EtOH, NaI, reflux, (vi) HCl, (vii)
POCl3, reflux, and (viii) H2NPhNR2, CHCl3, rt.
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third groove, between the extreme 59 end of the sequence and
residues 13–15, has a narrowed width of ,6 Å.
Initial molecular modeling studies on further compounds, with
aliphatic substituents at the 9-position, indicated that these would
sit directly in the third groove, resulting in an increased interaction
energy. These models suggested that the ideal chain length was only
ca. 4–5 carbon atoms to maximize the van der Waals interactions
in the third groove, by contrast with the longer amidoalkylamino
side chains. This shorter distance is brought about by the slightly
closer position of the acridine chromophore to the third groove.
Hence, any substituent at this position could potentially introduce
steric clashes with the adjacent G quartet interfering with the
essential 3.4-Å stacking interactions. Models of these systems
indicated that direct attachment of an aliphatic carbon linker to the
chromophore would indeed produce such steric clashes. The orig-
inal side chains in 1 and other compounds incorporate an amide
functionality that conjugates with the ring system and maintains
planarity to the edge of the G quartet, thus eliminating any potential
steric clashes. By analogy we have found that an amine at the
9-position is not only a synthetically accessible linker, but crucially
can be readily accommodated in the binding site without steric
hindrance. An aryl substituent attached to the amine would then
effectively occupy the space in the third groove.
The first two compounds, 3 and 4, in this generation of acridine
molecules are shown in Fig. 1, having anilino subsituents at the
9-position. Retention of the acridine chromophore ensures that
electrostatic interactions are maximized with the top of the central
G quartet channel, which has a region of negative electrostatic
potential arising from the O6 oxygen atoms of the guanines. The
calculated relative binding energies for these compounds are shown
in Table 1 and clearly indicate that substitution at the 9-position on
the acridine chromophore significantly increases the interaction
energy between the ligand and the intramolecular human quadru-
plex structure. Fig. 3 b and c shows the final position of compound
3 after 1 ns of unrestrained molecular dynamics. All of the side
chains reside in their respective separate grooves without significant
conformational changes in the drug molecule. The solvent acces-
sible surface area is shown in Fig. 3c, where the drug molecule in
yellow complements the surface area of the binding site. Over the
trajectory the narrow groove containing the anilino moiety expands
to accommodate the aromatic ring, so that all of the grooves
become almost identical in width. The slight difference in binding
energy between the dimethyl anilino derivative (compound 3) and
the free amine derivative (compound 4) can be attributed to the
protrusion of the N-dimethyl moiety into bulk solvent, which thus
loses interaction energy with the groove compared with the NH2
group in 4. Modeling (detailed elsewhere) also indicated that a
B-form DNA duplex, with just two grooves, could only accommo-
date these tri-substituted molecules with substantial distortion to
avoid steric clashes with backbones.
On the other hand, we find that compound 2 is unable to bind
effectively, as described (20), due to the large size of the groups
at the end of the two side chains, preventing them from forming
these favorable contacts.
Interactions with Quadruplexes in Solution. The binding of all four
ligands to the human quadruplex and a representative duplex
structure was examined by SPR techniques, with the DNA se-
quences immobilized on chips (Fig. 4). This has provided quanti-
tative estimates of binding affinities and onyoff rates of reaction.
The SPR data for all four compounds shows in each case a
single strong quadruplex binding site, although weaker ones are
also present. The data in Tables 2 and 3 shows that there are
marked differences in their affinities for different DNA struc-
tures, especially when compared with their binding to duplex
DNA. The disubstituted compound 1 has approximately the
same binding constant for duplex and quadruplex, whereas the
two trisubstituted compounds 3 and 4 bind to human quadruplex
Fig. 3. (a) View of the simulated structure of compound 1 bound to the
high-affinity binding site in the human quadruplex structure formed from the
sequence d[AG3(TTAG3)3], looking onto the terminal guanine quartet. (b)
View of the complex with compound 3 bound in the same site, at the end of
a 1-ns molecular dynamics simulation. (c) Overall view of the complex with
compound 3 (shown as a solvent-accessible surface, with nitrogen atoms
highlighted in blue). The two sodium atoms in the central channel of the G
quartet are shown in mauve.
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DNA 30–40 times more strongly than to duplex. Their affinity
for the quadruplex is 10-fold higher than that of compound 1.
Compound 2 is the weakest duplex and quadruplex binder of the
series.
The kinetics of interactions between the four acridine com-
pounds and the human telomeric DNA G quadruplex also were
examined by SPR experiments. High flow rates were used to
minimize the effects of mass transport and deliver a consistent
sample plug. To collect kinetic data, a range of concentrations of
the acridine were injected over the immobilized DNA and reference
surface. Responses from the reference surface were used to correct
for refractive index changes and instrument noise. A detailed
kinetic analysis was performed by globally fitting the association
and dissociation phase data for each compound binding to the G
quadruplex (Fig. 4a). The rate constants are shown in Table 2. The
association rate for compound 1 was approximately twice as fast as
that for 4 and more than five times that for 3. Compound 2 was the
slowest. The dissociation rate for 1 was approximately 1 order of
magnitude faster than that for 4 and 20 times that for 3. Together
these rate constants predict equilibrium association constants for
compounds 3 and 4 binding to quadruplexes, which are an order of
magnitude higher than that for 1.
We conclude that the trisubstituted compounds demonstrate
significant quadruplex selectivity both in thermodynamic and
kinetic terms.
Telomerase Inhibition and Cytotoxicity. The TRAP assay used to
assess telomerase activity uses PCR amplification of the telomere
primer strand. To eliminate false positives in this assay, we used an
initial screen with TAQ polymerase, which also helps to identify
nonspecific polymerase activity. None of the three compounds in
this study were active against TAQ polymerase at concentrations
,20 mM. Table 4 summarizes telomerase inhibitory activity and
cytotoxicity in three human ovarian carcinoma cell lines, expressed
as IC50 values, i.e., the concentrations required to inhibit activity
and cell growth respectively by 50%. The activity of the disubsti-
tuted acridine 1 is typical of the more active anthraquinones,
acridines, and other G-quadruplex inhibitors previously reported
(16–19). Compound 2 is essentially inactive as a telomerase inhib-
itor, although it retains the high cytotoxicity of compound 1. The
two trisubstituted compounds 3 and 4, on the other hand, show
telomerase activity at levels of up to ca. 100-fold greater potency.
Both are also significantly less potent in the cytotoxicity assay, with
compound 4 having outstandingly low activity (as well as being the
most potent telomerase inhibitor).
Conclusions
There are several lines of evidence supporting the hypothesis of
G-quadruplex mediation in the inhibition of telomere elongation by
ligands. For example, primer extension results with disubstituted
amidoanthraquinones are consistent with the formation of a 3–4
repeat intramolecular quadruplex (16). Structure-activity studies
with a series of acridines and anthraquinones disubstituted withFig. 4. (a) A set of SPR sensorgrams for binding of compound 3 to the human
G quadruplex at 25°C is shown. The unbound ligand concentrations in the flow
solution were 0, 5, 10, 20, 40, 60, 80, 100, 200, and 600 nM from the lowest
curve to the top curve. The lines are linear best fits to the steady-state RU
(response units) values, which are directly proportional to the amount of
bound compound, and were used to determine the RU for each free ligand
concentration. (b) The RU values from the steady-state region from a plotted
versus the unbound compound 3 ( n ) concentration. Experiments similar to
those in a also were conducted for compound 1 (F) and curves for the two
derivatives are shown. The lines were obtained by nonlinear least-square fits
of the data. Results for compound 4 were similar to those for 3. Equilibrium
constants for all compounds are given in Table 3.
Table 2. Rate constants for quadruplex interactions, determined
from BIAcore analysis
Compound ka (M21zs21) kd (s21)
1 1.3 3 106 0.272
2 4.6 3 104 0.090
3 2.4 3 105 0.018
4 6.6 3 105 0.029
Table 1. Computed interaction energies for the complexes of the three acridine derivatives
with the human intramolecular quadruplex, in kcal mole21
Acridine
derivative
Average interaction
energy DNA-ligand complex
Average interaction
energy for ligand
Relative DNA-ligand
binding energy
1 2157.3 296.3 261.0
3 2223.6 2132.9 290.7
4 2220.5 2115.3 2105.2
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progressively increasingly bulky substituents have demonstrated a
close relationship between telomerase inhibition and predicted
binding energy for the human quadruplex (20). The present study
confirms and extends these conclusions, with the successful design
of ligands that couple enhanced quadruplex affinity with increased
telomerase potency. On the other hand, compound 2, with in-
creased steric bulk such that it cannot as effectively interact with the
quadruplex binding site, is a poor telomerase inhibitor. The im-
provement in telomerase inhibitory activity shown by the trisubsti-
tuted acridines compared with disubstituted one, is qualitatively
what would be expected on the basis of their differences in
quadruplex affinity alone. It also suggests that further improve-
ments in both quadruplex selectivityyaffinity and telomerase ac-
tivity may be expected upon the incorporation of further appro-
priate functionality to these and other ligands. Fine-tuning of ligand
design and crystallographic studies (if feasible) also may enable one
to differentiate between different types of inter and intramolecular
quadruplexes that can in principle be formed.
The present results also provide further support for models with
ligand bound on the exterior of the stack of G quartets in a
quadruplex (21, 25). Alternative models, in which a ligand is
intercalated within the stack, are not in accord with NMR evidence
(21) or detailed molecular dynamics studies (25). Unwinding and
opening up of a G quartet stack (and disruption of the metal-ion
structure) would be expected to be exceptionally slow, and is not
consistent with the kinetic data in Table 2. Future crystallographic
studies will undoubtedly resolve this issue.
The classic model for telomerase activity focuses on its role of
catalyzing telomere length extension, with inhibition resulting in
telomere shortening and senescence. There is recent evidence of an
additional and more complex role for the enzyme, of capping
telomere ends and so protecting them from entering DNA damage
pathways (30, 31). In this way telomerase maintains the integrity of
the very short telomeres characteristic of many tumor cells. A
consequence of this model is that interference with the capping
function will lead to the activation of DNA damage response and
eventual cell death. The folding of telomeric ends into higher-order
quadruplex structures is known to inhibit telomerase catalytic
activity (14), probably by disallowing the initial template-primer
recognition from occurring. Thus the action of quadruplex-selective
ligands, such as are described here, is fully consistent with the
capping model, and moreover provides an explanation for findings
(S.H.G. and L.A.K., unpublished observations) of cellular senes-
cence produced by compounds 3 and 4 in the absence of significant
telomere shortening.
Telomerase-negative (ALT) mechanisms of telomere mainte-
nance are likely to involve end-to-end recombination events (33)
such as higher-order telomeric DNA formation and disassembly
promoted by helicases. One such, the Bloom’s syndrome helicase is
implicated in the high level of recombination events that charac-
terize this disorder and has also been found to unwind quadruplex
DNA (34) more readily than duplex DNA. The perylene quadru-
plex-interactive ligand (21) has been found (32) to inhibit the
unwinding of the analogous helicase from Saccharomyces cerevisiae,
suggesting that it and other G4 ligands may be effective inhibitors
of G4-mediated recombination in general, and perhaps of ALT
mechanisms in particular. This would give G4-interactive ligands
the therapeutic advantage over other categories of telomerase
inhibitors (11, 12), of being active in telomerase-negative ALT cell
lines.
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Table 4. Telomerase inhibition, and cytotoxicity, given as EC50
and IC50 values in mM
Compound telEC50 A2780 IC50 CH1 IC50 SKOV-3 IC50
1 5.2 2.65 8.2 2.6
2 .50 1.3 2.2 2.3
3 0.095 10 10.1 13
4 0.06 .25 .25 .25
Table 3. Equilibrium binding constants to duplex and
quadruplex DNA
Compound K (duplex) K (quadruplex)
1 1.1 3 106 1.3 3 106
2 2 3 105 8.3 3 105
3 4 3 105 1.6 3 107
4 5 3 105 1.6 3 107
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